Aktis Oncology Inc., a clinical-stage biotechnology company that counts Eli Lilly & Co. among its backers, raised $317.7 million in an initial public offering priced at the top of the marketed range.
The Boston-based firm sold 17.65 million shares at $18 each, according to a statement Thursday. The listing also drew interest from Eli Lilly for about $100 million shares, according to an earlier filing with the US Securities and Exchange Commission.
The company had marketed the shares at $16 to $18 apiece in the offering, which was increased from 11.8 million shares Wednesday.
At the IPO price, Aktis ...
